A Software to Prevent Delirium (PREVEDEL) in Hospitalized Older Adults (PREVEDEL)

Software-guided Cognitive Stimulation Prevents the Development of Delirium in Hospitalized Older Adults: Randomized Controlled Trial

Background

Delirium, is a clinical condition characterized by acute and fluctuating deterioration of the cognitive state, generally secondary to an acute pathology. It is a common condition in hospitalized older adults and it develops in 20-30% of patients hospitalized in a general ward and up to 80% of those hospitalized in critical care units. Delirium is associated with negative outcomes in older adults, such as longer hospitalizations, higher mortality, and short and medium-term institutionalization. Randomized clinical trials have shown that delirium is preventable through non-pharmacological prevention measures, decreasing its incidence by 30 to 50%. These interventions include promoting physical activity, facilitating the use of glasses and hearing aids, cognitive stimulation, and providing frequent reorientation of time and space, among others.

These measures are currently seldom applied in hospitals in Chile and around the world for various reasons some of which include the heavy workload of clinical staff, the lack of trained personnel, and, in general, the absence of systematic implementation processes.

The main objective is to evaluate whether cognitive stimulation guided by PREVEDEL software prevents delirium status(full/subsyncromal delirium) in hospitalized older adults.

Method/Design: randomized controlled trial, parallel groups, multicenter.

Participants: patients 65 years or older who have been hospitalized for less than 48 hours in the general ward or in the intermediate care unit of 4 hospitals in Santiago, Chile.

Intervention: participants in the intervention group will use a tablet with cognitive stimulation software for delirium prevention for 5 continuous days versus the control group who will use the tablet without the software.

Evaluations: The incidence of delirium and subsyndromal delirium, duration, density of delirium, cognitive and functional status at discharge, adherence to prevention measures, as well as demographic variables of interest will be evaluated.

Study Overview

• Status: Recruiting
• Conditions: Neurologic Manifestations; Delirium; Confusion; Neurobehavioral Manifestations
• Intervention / Treatment: Other: Placebo; Other: Implement a program of non-pharmacological interventions to prevent delirium; Other: Prevention software

Detailed Description

Background. Delirium is a clinical condition characterized by acute cognitive impairment, of fluctuating course, generally secondary to an acute pathology, which appears after the interaction between predisposing factors and well described precipitants. It is a very common condition in older adults, observed in 20% to 30% of patients hospitalized in a general ward, and up to 80% of those hospitalized in critical care units. Delirium is associated with negative clinical outcomes which include longer hospitalizations, increased direct and indirect costs, functional impairment, greater risk of mortality, increased risk of institutionalization, and deterioration in long-term cognitive status, among others.

Subsyndromal delirium (SSD) is a milder state characterised by the presence of certain delirium symptoms but without meeting full diagnostic criteria thresholds, is also associated with poor posthospitalization outcomes similar to those associated with delirium. The reported frequency of subsyndromal delirium varies (7-50%) according to the definition applied and the clinical population studied. Its incidence in the general medicine ward is 17%.

The frequency of delirium status (full/subsyndromal delirium) in the general room is approximately 25%.

It is known that delirium in hospitalized older adults is preventable. In multiple randomized clinical trials, non-pharmacological interventions to prevent delirium (nPPD), shown to reduce its incidence by 30-50%7.

Despite the high evidence supporting them, non-pharmacological interventions to prevent delirium are poorly implemented in hospitals in Chile and around the world for several reasons, such as the heavy workload of clinical staff, lack of trained personnel, and, in general, the absence of systematic implementation processes.

Prior to this clinical trial, local pilot studies have shown some progress in this area. On the one hand, it has been reported that the incorporation of software technology through a "PREVEDEL" tablet is feasible and can be implemented on a hospital level, with possible effects on decreasing delirium. On the other hand, the implementation of nPPD following a theoretical model improves the adherence of health personnel.

Therefore, a multicenter randomized clinical trial is proposed, which seeks to evaluate whether cognitive stimulation guided by the PREVEDEL software prevents delirium in hospitalized older adults and whether it is a technology that can be used in others hospital centers.

Centers and place where data is collected. Chile. These are: Hospital Clínico de la Universidad de Chile (HCUCH), Hospital San Juan de Dios (HSJD), Clínica Las Condes (CLC) and Hospital Santiago Oriente Dr. Luis Tisné (HLT). Two are public institutions and two are private institutions.

Intervention.

Interventions to implement a program of non-pharmacological interventions to prevent delirium (nPPD) in the centers that will participate in the RCT.

Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study

Interventions to perform an RCT where the effect of the use of PREVEDEL versus a placebo (Tablet without PREVEDEL) in the prevention of delirium in older adults is compared.

Standard non-pharmacological prevention measures

According to the recommendations in the literature and those made by local studies, the following standard non-pharmacological delirium prevention measures were defined:

Study groups Control Group: will receive the standard delirium prevention measures outlined above, plus the use of a mobile device without delirium prevention software for 5 days (Control Group: nPPD package, without PREVEDEL).

Experimental Group: will receive the standard delirium prevention measures, plus the use of a mobile device with PREVEDEL software for 5 days (Experimental Group: nPPD package, with PREVEDEL).

To evaluate patient adherence and how the tablet is used, both groups will have an application installed in their devices that will allow them to keep track of the time of use and applications used.

Software content

1. Desktop module.
2. The exercise module.
3. Games module.
4. The documentary module.
5. Alert module.
6. Configuration module, allows software customization.
7. Registration system.

OBJECTIVES AND HYPOTHESIS

General To assess whether cognitive stimulation guided by PREVEDEL software prevents delirium status in hospitalized older adults.

Specifics

• Implement a program of nPPD at the centers that will participate in the randomized clinical trial (RCT).
• Conduct a randomized clinical trial (RCT) comparing the effect of the use of PREVEDEL versus placebo (Tablet without PREVEDEL) in the prevention of delirium in older adults.

Hypothesis Cognitive stimulation guided by PREVEDEL software decreases the incidence of delirium status in hospitalized older adults.

Study sample.

For the calculation of the sample size, local and literature data were considered. A delirium status prevalence of 20% is estimated in the Control group and a decrease of this to 8% in the Intervention group. In this way, with a power of 80%, and an alpha of 0.05 bilaterally, 147 patients will be enrolled in each group. If add to this a 10% loss of follow-up, the overall sample size is 320 patients.

Randomization. Randomization was performed with computer-generated random permuted blocks using a centralized, secure Web-based randomization service.

Masking The enrollers, evaluators and healthcare personnel (nurses, physical therapists, physicians, occupational therapists) do not know the assigned group. Both groups receive a tablet of the same dimensions and with the same basic applications. However, blinding the patient is not possible, since when exploring the tablet, he or she will recognize whether or not it has the PREVEDEL program included. To reduce this bias, the staff that delivers the tablet encourages both groups to use its different basic applications (access the Internet) and that any doubts may have participants about its use should be made to the tablet coordinator, so that the evaluators or healthcare personnel remain masked.

The time between assignment and delivery of the tablet is between 4 to 12 hours in all participating centers. This variable will be measured for later analysis.

Statistical Methods For the descriptive analysis of the variables will use the mean (standard deviation), median (25-75 percentiles), or proportions as appropriate to the type and distribution of the data.

Analytical Statistics: For the primary outcome, a comparison of proportions between patients who develop delirium and subsyndromal delirium in both groups will be made, using Fisher's exact test, and as a measure of efficacy, an OR (95% CI) will be estimated. If there is any baseline variable that is not matched by the randomization, efficacy analyses will be carried out by means of logistic regression with the main variable being the treatment, and the adjustment variables those that the randomization would not have been able to match. Additionally, to compare the effect of the intervention over time, a time-to-event analysis will be performed using the Kaplan-Maier procedure and then the Cox regression model to adjust for baseline variables and the presence of the intervention. For the secondary outcomes, the Fisher's exact test or t-Test will be used, as appropriate, for the type and distribution of the data. Linear regression or multivariate logistics will also be performed, as appropriate, to evaluate the impact of the intervention, adjusting for the input covariates. A bilateral p 0.05 significance level will be used for all analyses.

Ethics Committee The research protocol was reviewed and approved by the ethics committee of the Clinical Hospital of the University of Chile and its approval was validated by the ethics committees of the respective participating centers (Registry No. 049, July 31, 2019).

Trial Steering Committee

Committee was formed with 3 international experts in the "Trial Steering Committee" (TSC) area. This committee will watch over the following aspects:

• Supervise and guarantee scientific quality.
• Advise on study protocol, recruitment progress, adherence, follow-up and data quality.
• Review the recommendations of the data analysis and monitoring committee.
• Review the publications in the primary trials.

For the fulfillment of the objectives, the TSC will meet before, in the middle and at the end of the recruitment.

Informed Consent The informed consent will be given by the patient himself and obtained by one of the main investigators.

• Study Type: Interventional
• Enrollment (Anticipated): 320
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Eduardo Tobar Almonacid, MD; Phone Number: +56992368717; Email: etobar@hcuch.cl
• Study Contact Backup: Name: Maricel A Garrido Montenegro, MSc; Phone Number: +56229788038; Email: mgarridom@hcuch.cl

Study Locations

• Chile
  • Metropolitana
    • Santiago, Metropolitana, Chile
      • Recruiting
      • University of Chile

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients 65 years or older.
• Hospitalized less than an 48 hours ago in a general ward or in the intermediate care unit. Participating health center: 1) Hospital Clínico de la Universidad de Chile, 2) Hospital San Juan de Dios, 3) Clínica Las Condes, 4) Hospital Santiago Oriente Dr Luis Tisné.

Exclusion Criteria:

• Presence of full or syndromal delirium (CAM+ or presence of one core elements).
• History of dementia (AD8 greater than 2 points).
• Non-Spanish speaking patients.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Control Group; will receive the standard delirium prevention measures outlined above, plus the use of a mobile device without delirium prevention software for 5 days (Control Group: nPPD package, without PREVEDEL).	Other: Placebo; All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.; Other: Implement a program of non-pharmacological interventions to prevent delirium; Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
EXPERIMENTAL: Experimental Group; will receive the standard delirium prevention measures, plus the use of a mobile device with PREVEDEL software for 5 days (Experimental Group: nPPD package, with PREVEDEL).	Other: Implement a program of non-pharmacological interventions to prevent delirium; Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.; Other: Prevention software; The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Delirium Status (delirium and subsyndromal delirium)	To evaluate the incidence of delirium and incidence of subsyndromal with Confusion Assessment Method (CAM).	5 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time of use of electronic device	The usage time on the mobile device (with internal device registration) will be recorded.	5 days
Duration of delirium	To evaluate duration in days.	5 days of protocol and 2 days of follow-up.
Density of delirium	Understood as the ratio between the duration of the event and the exposure time (time spent in the protocol).	5 days.
Level of independence in basic activities of daily living	To evaluate level of independence in activities of daily living at discharge with Functional Independence Measure.Scoring ranges from 13 to 126 points, with higher scores indicative of better performance.	At day 0 and 5.
Cognitive level	Evaluate cognitive performance at hospital discharge with Montreal cognitive Assessment. Scoring ranges from 0 to 30 points, with higher scores indicative of better performance.	At day 0 and 5.
Adherence to prevention measures	Assessment of adherence to 4 non-pharmacological prevention domains (12 indicators): Management of environment (visible clock, visible calendar, decrease physical restrictions, early mobilization), (indication of relative rest, encourage patient to sit and stand), correction of sensory deficits (availability of glasses, hearing aids, and dentures when necessary), management of medications (decrease the use of benzodiazepines, anticholinergics, and metoclopramide when possible).	At day 0 and 30 (before and after training in prevention measure).
Hospital stay	Length of hospital stay in days.From the day of admission to the hospital until discharge.	Through study completion an average of 30 days
90-day mortality	90-day mortality check by civil registry.	At 90 day.
Difficulty falling and staying asleep due to device use.	Every day when removing the device, the person will be asked ¿Have you had difficulty falling and staying asleep due to device use?	Every day for 5 days.
Headache due to the device use.	Every day when removing the device, the person will be asked Have you had a headache due to the device use? If the answer is yes, the intensity of the pain will be scored, where 0 is no pain and 10 is the greatest pain.	Every day for 5 days.

Collaborators and Investigators

• Sponsor: University of Chile

Publications and helpful links

General Publications

• Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014 Mar 8;383(9920):911-22. doi: 10.1016/S0140-6736(13)60688-1. Epub 2013 Aug 28.
• Saczynski JS, Marcantonio ER, Quach L, Fong TG, Gross A, Inouye SK, Jones RN. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012 Jul 5;367(1):30-9. doi: 10.1056/NEJMoa1112923.
• Veiga D, Luis C, Parente D, Fernandes V, Botelho M, Santos P, Abelha F. Postoperative delirium in intensive care patients: risk factors and outcome. Rev Bras Anestesiol. 2012 Jul;62(4):469-83. doi: 10.1016/S0034-7094(12)70146-0.
• Leslie DL, Zhang Y, Holford TR, Bogardus ST, Leo-Summers LS, Inouye SK. Premature death associated with delirium at 1-year follow-up. Arch Intern Med. 2005 Jul 25;165(14):1657-62. doi: 10.1001/archinte.165.14.1657.
• Sepulveda E, Leonard M, Franco JG, Adamis D, McCarthy G, Dunne C, Trzepacz PT, Gaviria AM, de Pablo J, Vilella E, Meagher DJ. Subsyndromal delirium compared with delirium, dementia, and subjects without delirium or dementia in elderly general hospital admissions and nursing home residents. Alzheimers Dement (Amst). 2016 Dec 1;7:1-10. doi: 10.1016/j.dadm.2016.11.002. eCollection 2017.
• Meagher D, O'Regan N, Ryan D, Connolly W, Boland E, O'Caoimhe R, Clare J, Mcfarland J, Tighe S, Leonard M, Adamis D, Trzepacz PT, Timmons S. Frequency of delirium and subsyndromal delirium in an adult acute hospital population. Br J Psychiatry. 2014 Dec;205(6):478-85. doi: 10.1192/bjp.bp.113.139865. Epub 2014 Oct 30.
• Abraha I, Trotta F, Rimland JM, Cruz-Jentoft A, Lozano-Montoya I, Soiza RL, Pierini V, Dessi Fulgheri P, Lattanzio F, O'Mahony D, Cherubini A. Efficacy of Non-Pharmacological Interventions to Prevent and Treat Delirium in Older Patients: A Systematic Overview. The SENATOR project ONTOP Series. PLoS One. 2015 Jun 10;10(6):e0123090. doi: 10.1371/journal.pone.0123090. eCollection 2015.
• Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, Cooney LM Jr. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999 Mar 4;340(9):669-76. doi: 10.1056/NEJM199903043400901.
• Alvarez EA, Garrido MA, Tobar EA, Prieto SA, Vergara SO, Briceno CD, Gonzalez FJ. Occupational therapy for delirium management in elderly patients without mechanical ventilation in an intensive care unit: A pilot randomized clinical trial. J Crit Care. 2017 Feb;37:85-90. doi: 10.1016/j.jcrc.2016.09.002. Epub 2016 Sep 10.
• Nydahl P, Dewes M, Dubb R, Hermes C, Kaltwasser A, Krotsetis S, von Haken R. Survey among critical care nurses and physicians about delirium management. Nurs Crit Care. 2018 Jan;23(1):23-29. doi: 10.1111/nicc.12299. Epub 2017 May 18.
• Xing J, Sun Y, Jie Y, Yuan Z, Liu W. Perceptions, attitudes, and current practices regards delirium in China: A survey of 917 critical care nurses and physicians in China. Medicine (Baltimore). 2017 Sep;96(39):e8028. doi: 10.1097/MD.0000000000008028.
• Alvarez EA, Garrido M, Ponce DP, Pizarro G, Cordova AA, Vera F, Ruiz R, Fernandez R, Velasquez JD, Tobar E, Salech F. A software to prevent delirium in hospitalised older adults: development and feasibility assessment. Age Ageing. 2020 Feb 27;49(2):239-245. doi: 10.1093/ageing/afz166.
• Garrido MA, Alvarez EA, Ponce DP, Salech F, Tobar DI, Tobar EA. Consolidated framework for advancing implementation science for the implementation process and adherence assessment of a non-pharmacological delirium prevention program. Int J Geriatr Psychiatry. 2021 Feb;36(2):302-313. doi: 10.1002/gps.5425. Epub 2020 Sep 16.
• Wei LA, Fearing MA, Sternberg EJ, Inouye SK. The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc. 2008 May;56(5):823-30. doi: 10.1111/j.1532-5415.2008.01674.x. Epub 2008 Apr 1.
• Young Y, Fan MY, Hebel JR, Boult C. Concurrent validity of administering the functional independence measure (FIM) instrument by interview. Am J Phys Med Rehabil. 2009 Sep;88(9):766-70. doi: 10.1097/PHM.0b013e3181a9f1d6.

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 1, 2021
• Primary Completion (ANTICIPATED): August 31, 2022
• Study Completion (ANTICIPATED): January 15, 2023

Study Registration Dates

• First Submitted: August 5, 2021
• First Submitted That Met QC Criteria: October 25, 2021
• First Posted (ACTUAL): November 4, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 4, 2021
• Last Update Submitted That Met QC Criteria: October 25, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: delirium; prevention; cognitive stimulation
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Neurocognitive Disorders; Delirium; Neurobehavioral Manifestations; Confusion; Neurologic Manifestations
• Other Study ID Numbers: ID16AM2080

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No